Open Access

Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC)

Contributed equally
Experimental Hematology & Oncology20132:15

https://doi.org/10.1186/2162-3619-2-15

Received: 19 February 2013

Accepted: 7 May 2013

Published: 20 May 2013

Abstract

Tumor-associated antigens (TAAs) recognized by cellular and/or humoral effectors of the immune system are attractive targets for diagnostic and therapeutic approaches to human cancer. Different approaches can be used to comprehensively characterize and validate the identified TAA/anti-TAA systems, which are potential biomarkers in cancer immunodiagnosis. Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. The high fatality rate of HCC within one year after its detection might be partly attributed to a lack of diagnostic methods that enable the early detection. Our previous studies have shown that novel autoantibodies can appear which are not detected prior to pre-malignant conditions during transition from chronic liver disease to HCC. The hypothesis we advance is the transition to malignancy can be associated with autoantibody response to certain cellular proteins that might have some role in tumorigenesis. We propose that the information that the cancer patient’s immune system is conveying in the form of autoantibodies to tumor-associated antigens (TAAs) should be utilized to a greater extent in identifying early signs of tumorigenesis. In this review, we will focus on the important features of TAA and the possibility that autoantibodies to TAAs can be used as biomarkers in immunodiagnosis and prognosis of HCC.

Keywords

Hepatocellular carcinomaTumor associate antigenAutoimmunityBiomarkerImmunoserological diagnosis

Introduction

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide. The majority of people with HCC will die within one year since they have been made a definite diagnosis. The high fatality rate of HCC can partly be attributed to a lack of sensitive detection method for HCC early diagnosis. Serum alpha fetoprotein (AFP) is the most effective marker available to detect HCC, however the sensitivity and specificity are not optimal, especially in patients with small tumors or in well-to-moderately differentiated HCC [13]. Therefore, it is necessary to develop more sensitive and specific methods for supplementing AFP in the early detection of HCC.

There are many studies demonstrating that the immune system can recognize the antigenic changes in cancer cells, and further develop autoantibodies against these antigens which have been called tumor-associated antigens (TAAs) [4, 5]. Therefore, these cancer-associated autoantibodies might be considered as “reporters” from the immune system, to identify the antigenic changes of cellular proteins involved in the transformation process [2, 5]. Research on autoantibody immunity to cancer-associated proteins has received great attention. As the detection of antibody immunity to tumor antigens becomes more routine, investigators have begun to address specific clinical application of cancer-associated autoantibody as a marker for detection of cancer, as a tool to monitor therapy, or as an indicator to predict disease prognosis. With the expending list of autoantibodies to TAAs, the identification of cancer-associated autoantibody signatures may therefore become useful as a tool for cancer diagnosis and prognosis [68].

The purpose of this review will focus on the recent advances in our studies primarily associated with the idea and possibility that detection of anti-TAAs autoantibodies can be useful for HCC immunodiagnosis.

This study was approved by the Institutional Review Board of The University of Texas at El Paso and collaborating institutions.

Tumor-associated antigens (TAAs) and autoantibodies

One of the most extensively studied TAAs is p53, the tumor suppressor protein, which is a phosphoprotein barely detectable in the nucleus of normal cells [9]. P53 can arrest cell-cycle progression on cellular stress, particularly induced by DNA damage, to allow the DNA to be repaired [10] or trigger a process that can lead to cell apoptosis [11]. Autoantibodies to p53 in cancer were first reported in 1982 [12] and since then there have been numerous reports confirming and extending this finding [13]. Antibodies to p53 have now been found in many types of cancer, including lung [14], esophageal [15], oral [16], colon [17], gastric [18], hepatic [19], breast [20] cancers. A review article demonstrated that p53 antibodies are a specific marker of patients with malignancy [13]. For several tumor sites a decline or even disappearance of p53 antibody levels few weeks after surgical tumor removal has been demonstrated, which is in line with the hypothesis that constant stimulation of the immune system by the antigen is necessary to maintain high antibody levels [2124]. These findings led to the suggestion that antibody serology might be a tool for detection of disease recurrence [25].

The types of cellular proteins inducing autoantibody responses are quite varied and include oncogene products such as HER-2/neu [26], cellular proteins which shield mRNAs from natural physiological degradation such as p62/IMP2 [27] and CRD-BP [28], onconeural antigens in the paraneoplastic disorder syndrome [29], differentiation-antigens such as tyrosinase and cancer/tetis antigens [30].

The approach used in our laboratory to identify TAAs has involved initially examining the sera from cancer patients using extracts of tissue culture cells as source of antigens in Western blotting or by indirect immunofluorescence (IIF) on whole cells. With these two techniques, sera with high-titered fluorescent staining and strong signals to cell extract have been identified and subsequently used as probes to immunoscreen cDNA expression libraries and isolate cDNA clones encoding targeted antigens. HCC1 [31], p62/IMP2 [27], p90 [32] and other several novel TAAs have been identified in this manner.

A major issue in the field of cancer immunodiagnosis is the definition of what constitutes a TAA. It is erroneous to include all cellular antigens identified by autoantibodies in cancer sera as TAAs, since some autoantibodies may exist in conditions that pre-date malignancy. Many antibodies to autologous cellular proteins can be detected in the sera of patients with cancer, and the reactive antigens have been called TAAs without considering the possibility that the autoantibodies might have existed in the patient before cancer. It indicates that autoantibodies from a cancer patient obtained at only one time point would not be necessarily represent immune responses to a TAA. Failing to recognize the likelihood of pre-malignant circulating antibodies would result in the inclusion of many antigens erroneously as TAAs. Further research should be needed to establish true tumor-related antigens and to exclude those that might have been present prior to malignancy. In the further analysis, anti-TAA autoantibodies may become useful diagnostic biomarkers only after it has undergone extensive trials with many cancer sera and also with many non-cancer control sera [33].

Hepatocellular carcinoma (HCC) is one of unique cancers since it could be followed up from a cohort of patients with chronic liver disease who will likely develop malignancy over a period time more than one decade. During transition from chronic liver disease to malignancy, novel autoantibodies have been observed to appear which are not detected prior to pre-malignant conditions [34]. As mentioned above, our previous studies have identified several novel TAAs including HCC1 [31], p62/IMP2 [27] and p90 [32], which might be potential biomarkers in cancer immunodiagnosis. Below will be a brief discussion of the identification and significance of each TAA we have identified in HCC.

HCC1/CAPER

HCC1/CAPER is the first HCC-associated TAA isolated and identified [31]. Serum from a patient NK at the time when cancer was diagnosed was used to immunoscreen a HepG2 cell line λ - zap cDNA expression library in attempt to clone genes encoding any of the protein antigens. HCC1/CAPER, one of six cDNA clones which were all different-length isolates, has a full-length sequence, encoding a protein of 530 amino acid and migrating at 64 kDa in SDS-PAGE. HCC1/CAPER was a novel gene with unknown function at that time since the nucleotide and protein sequences were not found in Genbank and EMBL and SwissProt databanks. HCC1/CAPER contained a RS (arginine-serine) motif in the NH-terminus and three RNA-binding, RNP-CS (ribonucleoprotein consensus sequence, which has paired RNP1 and RNP2 regions) in the rest of the molecule. The structural peptide motifs of HCC1/CAPER were most similar to U2AF65, a smaller protein of 475 amino acid whose function was already characterized and shown to be an alternative splicing factor involved in pre-mRNA processing [31]. Other proteins with somewhat similar domain structure, such as SC35 [35] and SF2/ASF [36] and SRp55 [37], were also splicing factors involved in mRNA processing. However, the role of HCC1/CAPER in constitutive splicing is poorly understood. And there was no indication as to how it might be involved in tumorigenesis.

Nine years later, Jung et al reported that HCC1/CAPER was a co-activator of activating protein-1 and estrogen receptors and proposed naming it CAPER [38]. Three years after that, O’Malley and his colleagues shows that HCC1/CAPER was also an alternative splicing factor involved in the regulation of calcitonin and Vascular endothelial growth factor (VEGF) gene expression [39, 40], confirming function that was expected of its peptide motifs. More interestingly, a recent study has reported that HCC1/CAPER may an important role in modulating the oncogenic activity of Rel/NF-kB, suggesting that a dominant-negative mutant of HCC1/CAPER enhanced vRel-mediated transformation [41]. In a recent study, autoantibody responses to HCC1 were extensively evaluated in sera from patients with HCC, liver cirrhosis and chronic hepatitis, and other type of cancer. The prevalence of autoantibodies against HCC1 was 20.1% in HCC sera, which was significantly higher than that in NHS (2.3%), but not for other type of cancer (unpublished data). With the further understanding of the function of HCC1/CAPER, we may consider HCC1/CAPER as a candidate TAA. Actually, it is almost 15 years later after the first report of the identification of HCC1/CAPER in liver cancer.

p62/IMP2 (IGF-II mRNA binding protein)

p62/IMP2 was firstly identified as an autoantigen by screening the sera from patients with HCC [27]. Later studies found that p62/IMP2 is a member of the IGF-II mRNA binding protein (IMP) family, containing four hnRNP K-homology (KH) domains and two RNA recognition motifs [42]. It is encoded by a splice variant of the IMP2 gene, thus is known as an IMP2 isoform. The IMP family (IMP1, IMP2 and IMP3) binds and regulates translation of insulin-like growth factor 2 mRNA. Members of this family are oncofetal proteins [43], which have been implicated in RNA localization, stability and translation that are essential for normal embryonic growth and development. The expression disappears from all tissues soon after birth but frequently re-express during the process of malignant transformation. The overexpression of these proteins has been detected in many types of tumors, [27, 44, 45] and it has been hypothesized that the proteins can mediate cell motility and invasion, and might be closely related to cancer.

Antibody to p62/IMP2 was present in 21% of patients with HCC but not in the precursor conditions of chronic hepatitis and liver cirrhosis [27]. Other proteins from the IMP family also show certain relationship to malignancy. IMP1, which is almost identical to mouse coding region determinant-binding protein (CRD-BP) [46] and closely related to chicken zip-code binding protein 1 (ZBP1), binds directly to and stabilizes oncogenic c-Myc and regulates its posttranscriptional expression and translation [47, 48]. IMP3 is orthologous to Xenopus Vg1RBP/Vera and mouse K-homology protein overexpressed in cancer (KOC), which has been shown to be transcriptionally overexpressed in cancer [49].

p90/CIP2A (Cancerous Inhibitor of PP2A)

CIP2A is another tumor-associated antigen migrating in SDS-PAGE gel as a protein of 90 kD (also known as p90) [32]. It was firstly identified when screening sera from patients with gastric and liver cancer [32]. This protein has been shown to inhibit PP2A (Protein phosphatase 2) function, as a result stabilize the oncogene c-myc in human malignancies. Phosphorylation is a key kind of posttranscriptional modifications, which is also critical for the process of malignancy. PP2A exerts its tumor suppressive effects through dephosphorylating substrates at Serine and Threonine residues. Current understandings of the role of p90/CIP2A in tumor formation and progression mainly focus on its ability to inhibit PP2A phosphatase activity to regulate c-myc stability [50]. Several groups have confirmed the importance of p90/CIP2A in tumor formation in different cancer types like breast cancer, prostate cancer, gastric cancer, non-small cell lung cancer, oral carcinoma, esophageal squamous cell carcinoma and chronic myeloid leukemia [5157].

Approaches to TAAs identification

Autoantibodies to TAAs have been reported in a variety of human cancers, providing an insight into the interplay between malignancies and the immune response, and giving rise to novel diagnostic and therapeutic concepts [5]. Experimental technologies for identification of tumor-associated antigens include display methods such as phage display, serological expression cloning analysis, and TAA arrays [58, 59]. The approaches we once used in identifying the TAAs involved examining the sera of cancer patients using extracts of tissue or cultured cells as a source of antigens in Western blotting or by indirect immunofluorescence on whole cells. These two commonly used techniques have helped us to identify sera which have strong signals on Western blotting or high fluorescent staining, and subsequently use the antibodies in these sera to isolate cDNA clones from cDNA expression libraries. In this case, several novel TAAs including HCC1/CAPER [31], SG2NA [60], p62/IMP2 [27], p90/CIP2A [32] were identified.

Serological analysis of recombination cDNA expression libraries (SEREX) [61] is a useful methodology in identifying tumor antigens to autoantibodies from patients with different types of cancer [5], which is a modified technology of our previously used approach [27, 31, 32, 60]. The rational of this method is that intracellular proteins which are involved in carcinogenesis are provoking autoantibody responses and therefore autoantibodies can be used to immunoscreen cDNA expression libraries to isolate, identify and characterize proteins which might potentially be involved in malignant transformation. SEREX has proven to be a powerful tool in identifying antibody targets in a number of tumor types, including lymphoma, leukemia, esophageal cancer, gastric cancer, etc. [62, 63]. The number of SEREX-defined antigens exceeds 2000 kinds, with approximately one-third defining novel genes at the time of their discovery [64]. Our approach was not restricted to use of cDNA libraries from autologous tumors because our previous studies had shown that antibodies in HCC sera were reactive with antigens expressed by a variety of tissue culture cell lines [27, 31]. Using this approach, we have successfully isolated several novel TAAs such as p62/IMP2 and p90/CIP2A.

An improvement of SEREX approach is to combine it with phage-display technology. The phage-display technology has been widely used since it was first introduced in 1985 [65]. It’s capable to generate and screen peptide libraries to identify ligands for many types of molecules. Screening the phage-displayed libraries needs fewer amounts of sera from patients and has higher efficiency. Tumor cell lines have been used as source of cDNA to construct phage display libraries to identify candidate TAAs in colorectal, breast, prostate, and ovarian cancer [59].

In recent years, proteomics have become a rapidly emerging set of technologies to identify TAAs [66]. The proteome-based methods enable us to screen a large number of sera individually and determine a large number of autoantigens. An advantage of this approach is to distinguish isoforms and detect autoantibodies directly against post-translational modifications (PTMs) of specific targets. In our experience, two-dimensional gel electrophoresis and mass spectrometry can be used to separate lysates from cancer cell lines and identify immunoreactive proteins. In recent several years, we have identified characterized a bunch of protein in HCC and other type of cancer as TAAs with proteomic approach [67, 68]. A schematic representation of the approaches for the TAA identification used in our lab has been published [69].

Using a mini-array of multiple TAAs to enhance autoantibody detection in HCC diagnosis

The unique feature of HCC is that antecedent chronic hepatitis and liver cirrhosis are common precursor conditions and during transition to malignancy some patients develop autoantibodies which are not present during preceding chronic liver disease phase [34, 70, 71]. It was shown that novel autoantibodies appeared during conversion to malignancy which were not present in the pre-malignant chronic liver disease phase. In HCC, where novel autoantibody responses are detected during conversion to malignancy, it has been proposed that characterization of the autoantigens driving the novel immune responses might provide insights into intracellular proteins participating in mechanisms leading to malignant transformation [1]. Many researchers have been interested in the use of autoantibodies as serological markers for cancer diagnosis, especially because of the general absence or a significantly lower frequency of these autoantibodies in normal individuals and in non-cancer conditions [7, 72]. Enthusiasm for this approach has been tempered by low sensitivity when individual antigen-antibody reactions were studied.

Antibody frequency to any individual TAA was variable but rarely exceeded 15-20% [7, 73]. We have observed that this drawback can be overcome by using a panel of carefully selected TAAs to achieve the sensitivity and specificity required to make immunodiagnosis a feasible adjunct to tumor diagnosis. This feature is one of the innovative notions in our studies. Previous observations show that antibodies to any individual antigen such as p53 [7], c-myc [7, 74], p62 [7] do not reach levels of sensitivity which could become routinely useful in diagnosis. Wang et al developed a phage-display library derived from prostate cancer tissue, and a phage protein microarray, to analyze autoantibodies in serum samples from patients with prostate cancer and controls [72]. In this study, a 22-phage-peptide detector was constructed for prostate cancer screening, with 81.6% sensitivity and 88.2% specificity, which indicated that combinations of multiple antigen-antibody systems might acquire higher sensitivity for diagnosis of cancer [72]. One of our previous studies showed that detection of autoantibodies in cancer can be enhanced by using a mini-array of seven TAAs as target antigens which included c-myc, p53, cyclin B1, p62/IMP2, Koc, IMP1 and survivin [7, 73]. Antibody frequency to any individual TAA ranged from 10.8 to 24.6% in HCC. With the addition of TAAs to a final total of seven antigens, there was a stepwise increase of positive antibody reactions up to 56.9% in HCC. In our further study, p16, a cyclin-dependent kinase inhibitor, was evaluated as a TAA and added into our previously constituted mini-array of seven TAAs. Antibody frequency to any individual TAA in HCC was variable from 9.9%-21.8% but rarely exceeded 20%. There was a stepwise increase of positive antibody reactions up to 59.9% with successive addition of TAAs to a final of eight antigens, which was significantly higher than the frequency of antibodies in chronic hepatitis (20%), liver cirrhosis (30%) and normal individuals (12.2%). The sensitivity on diagnosing HCC was 59.9%, and the specificity was 87.8%, 80% and 70%, respectively, compared to normal individuals, chronic hepatitis and liver cirrhosis [75]. The data from our studies indicates that the combination of antibodies might acquire higher sensitivity for diagnosis of cancer.

Nevertheless, in the selection of different antigen-antibody systems, some of the antigens may turn out to be more specific for a certain type of cancer while others may be not. It is conceivable that autoantibody profiles involving different panels or arrays of TAAs might be developed and the results could be useful for diagnosis of certain types of cancer. We stress the notion that panels of “customized” TAAs should be used for different types of tumor and that these customized panels should be rigorously tested for sensitivity and specificity not only against other tumors but also against other diseases conditions. In the case of HCC, the natural conditions could be chronic hepatitis and liver cirrhosis. The basis for the notion of the necessity of customized panels of TAAs is based not only on empirical observations but also on retrospective analysis of our own data learned from previously published work [7, 34, 71, 73]. The main focus of our studies is to identify a specific panel of TAAs for HCC and compare and contrast this with antigen panels associated with chronic hepatitis and liver cirrhosis.

Possibility for anti-TAAs antibody as prognosis indicator

It is of great importance to find early detection of cancer in clinical oncology, which allows an effective and probably curative therapeutic management [10]. In the meanwhile, the prognosis of a patient diagnosed with cancer is considered as the chance that the disease will be cured and the patient will recover. It is known that various factors can affect the prognosis of a patient with cancer, including the biological and genetic properties of the cancer cells, which are also known as biomarkers and can be determined by certain tests. The potential utility of anti-TAAs antibody as early cancer biomarker or indicators of disease prognosis has been explored, since these anti-TAA antibodies are generally absent, or present in low frequency in normal individuals and in non-cancer conditions.

More and more evidences have shown that the immune system of the cancer patient is able to sense abnormalities in structure, function, intracellular location and other alterations of cellular participants in tumorigenesis [2]. Although most current studies are focusing on cancer autoantibodies as diagnostic biomarkers, it is likely that autoantibodies can also be used as monitors of therapeutic response, thus contributing to cancer prognosis. It is hypothesized that in a patient where a certain anti-TAA antibody is detected, change in antibody levels might reflect change in tumor status or tumor burden related to therapy [2].

Currently, although the continuous development and progress have been made in early diagnosis and treatment of cancer, however we are still facing problems to find sensitive and accurate biomarkers for cancer diagnosis, prognosis and treatment. Molecular studies using TAA-based arrays have identified several cancer related proteins involved in cell proliferation and metastasis during the process of tumorigenesis [76]. Such proteins have been detected in patients’ serum, which distinguish diseased individuals from healthy controls. Using TAA-array technique might be a useful tool to determine the groups of cancer patients with certain clinical outcomes, and consequently benefit to personalized treatment. Thus, it is of great importance to determine reliable biomarkers with high prognostic value.

Conclusions

In the past few years, the potential utility of autoantibody to TAAs as cancer biomarker for early detection or as indicators of disease prognosis has been explored. Our efforts will be aimed at increasing both the sensitivity and specificity of antibodies as markers in HCC by expending TAA array to include antigens which might be more selectively associated with HCC and not with others. It is expected that our mini-array of multiple TAAs can be used as a novel non-invasive approach to identify HCC in normal population and also in high-risk individuals such as patients with chronic hepatitis and liver cirrhosis. We predict that, in the next five years, the research on the cancer TAA autoantibody biomarkers will become a challenging field. With the data at hand, we know that many TAAs are not unique to any particular type of solid tumor and this should not be unexpected since tumorigenesis pathways are common to many tumors. Waiting for the generation of TAA arrays for immunodiagnosis of specific cancers, however, should not preclude taking advantage of the sensitivity of the anti-TAA/TAA systems in the initial screening process for early detection of cancer. Important additional studies will be needed to determine whether antibodies to a mini-arrays of multiple TAAs might be useful in identifying in early stage of certain types of other cancer in high-risk individuals.

Notes

Abbreviations

AFP: 

Alpha fetoprotein

CAPER: 

Co-activator of activating protein-1 and estrogen receptors

CIP2A: 

Cancerous inhibitor of PP2A

CRD-BP: 

Coding region determinant-binding protein

HCC: 

Hepatocellular carcinoma

IIF: 

Indirect immunofluorescence

KOC: 

K-homology overexpressed in cancer

SEREX: 

Serological analysis of recombination cDNA expression libraries

TAAs: 

Tumor-associated antigens

ZBP1: 

Zip-code binding protein 1.

Declarations

Acknowledgement

This work was supported by grants from NIH (SC1CA166016 and 5G12MD007592).

Authors’ Affiliations

(1)
Department of Biological Sciences, The University of Texas at El Paso

References

  1. Tan EM: Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 2001,108(10):1411–1415.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Tan EM, Zhang J: Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev 2008, 222: 328–340. 10.1111/j.1600-065X.2008.00611.xPubMed CentralView ArticlePubMedGoogle Scholar
  3. Kondo F, Wada K, Nagato Y, Nakajima T, Kondo Y, Hirooka N, Ebara M, Ohto M, Okuda K: Biopsy diagnosis of well-differentiated hepatocellular carcinoma based on new morphologic criteria. Hepatology 1989,9(5):751–755. 10.1002/hep.1840090516View ArticlePubMedGoogle Scholar
  4. Houghton AN: Cancer antigens: immune recognition of self and altered self. J Exp Med 1994,180(1):1–4. 10.1084/jem.180.1.1View ArticlePubMedGoogle Scholar
  5. Old LJ, Chen YT: New paths in human cancer serology. J Exp Med 1998,187(8):1163–1167. 10.1084/jem.187.8.1163PubMed CentralView ArticlePubMedGoogle Scholar
  6. Bradford TJ, Wang X, Chinnaiyan AM: Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer. Urol Oncol 2006,24(3):237–242. 10.1016/j.urolonc.2005.11.033View ArticlePubMedGoogle Scholar
  7. Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK, Tan EM: Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003,12(2):136–143.PubMedGoogle Scholar
  8. Draghici S, Chatterjee M, Tainsky MA: Epitomics: serum screening for the early detection of cancer on microarrays using complex panels of tumor antigens. Expert Rev Mol Diagn 2005,5(5):735–743. 10.1586/14737159.5.5.735View ArticlePubMedGoogle Scholar
  9. Benchimol S, Pim D, Crawford L: Radioimmunoassay of the cellular protein p53 in mouse and human cell lines. EMBO J 1982,1(9):1055–1062.PubMed CentralPubMedGoogle Scholar
  10. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991,51(23 Pt 1):6304–6311.PubMedGoogle Scholar
  11. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991,352(6333):345–347. 10.1038/352345a0View ArticlePubMedGoogle Scholar
  12. Crawford LV, Pim DC, Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982,30(4):403–408. 10.1002/ijc.2910300404View ArticlePubMedGoogle Scholar
  13. Soussi T: p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000,60(7):1777–1788.PubMedGoogle Scholar
  14. Park Y, Kim Y, Lee JH, Lee EY, Kim HS: Usefulness of serum anti-p53 antibody assay for lung cancer diagnosis. Arch Pathol Lab Med 2011,135(12):1570–1575. 10.5858/arpa.2010-0717-OAView ArticlePubMedGoogle Scholar
  15. Zhang J, Xv Z, Wu X, Li K: Potential diagnostic value of serum p53 antibody for detecting esophageal cancer: a meta-analysis. PLoS One 2012,7(12):e52896. 10.1371/journal.pone.0052896PubMed CentralView ArticlePubMedGoogle Scholar
  16. Porrini R, Vercellino V, Rocchetti V, Reno F, Giorda E, Pomato E, Cannas M, Sabbatini M: Serum anti-p53 antibodies as a diagnostic tumor marker: observations in patients with malignant and premalignant oral cavity lesions. Minerva Stomatol 2010,59(5):233–239. 239–243PubMedGoogle Scholar
  17. Ochiai H, Ohishi T, Osumi K, Tokuyama J, Urakami H, Seki S, Shimada A, Matsui A, Isobe Y, Murata Y, Endo T, Ishii Y, Hasegawa H, Matsumoto S, Kitagawa Y: Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients. Surg Today 2012,42(2):164–168. 10.1007/s00595-011-0044-1View ArticlePubMedGoogle Scholar
  18. Mattioni M, Soddu S, Porrello A, D’Alessandro R, Spila A, Guadagni F: Serum anti-p53 antibodies as a useful marker for prognosis of gastric carcinoma. Int J Biol Markers 2007,22(4):302–306.PubMedGoogle Scholar
  19. Liu J, Ma Q, Zhang M, Wang X, Zhang D, Li W, Wang F, Wu E: Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis. Eur J Cancer 2012,48(15):2328–2338. 10.1016/j.ejca.2012.03.001PubMed CentralView ArticlePubMedGoogle Scholar
  20. Ye H, Sun C, Ren P, Dai L, Peng B, Wang K, Qian W, Zhang J: Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer. Oncol Lett 2013,5(2):663–668.PubMed CentralPubMedGoogle Scholar
  21. Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T, Kobayashi S, Ochiai T: Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 2000,89(8):1677–1683. 10.1002/1097-0142(20001015)89:8<1677::AID-CNCR5>3.0.CO;2-9View ArticlePubMedGoogle Scholar
  22. Lubin R, Zalcman G, Bouchet L, Tredanel J, Legros Y, Cazals D, Hirsch A, Soussi T: Serum p53 antibodies as early markers of lung cancer. Nat Med 1995,1(7):701–702. 10.1038/nm0795-701View ArticlePubMedGoogle Scholar
  23. Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA, Bunting PS: Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994,58(4):480–487. 10.1002/ijc.2910580404View ArticlePubMedGoogle Scholar
  24. Hammel P, Boissier B, Chaumette MT, Piedbois P, Rotman N, Kouyoumdjian JC, Lubin R, Delchier JC, Soussi T: Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut 1997,40(3):356–361.PubMed CentralView ArticlePubMedGoogle Scholar
  25. Reuschenbach M, von Knebel Doeberitz M, Wentzensen N: A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 2009,58(10):1535–1544. 10.1007/s00262-009-0733-4PubMed CentralView ArticlePubMedGoogle Scholar
  26. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA: High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997,15(11):3363–3367.PubMedGoogle Scholar
  27. Zhang JY, Chan EK, Peng XX, Tan EM: A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med 1999,189(7):1101–1110. 10.1084/jem.189.7.1101PubMed CentralView ArticlePubMedGoogle Scholar
  28. Doyle GA, Bourdeau-Heller JM, Coulthard S, Meisner LF, Ross J: Amplification in human breast cancer of a gene encoding a c-myc mRNA-binding protein. Cancer Res 2000,60(11):2756–2759.PubMedGoogle Scholar
  29. Keene JD: Why is Hu where? Shuttling of early-response-gene messenger RNA subsets. Proc Natl Acad Sci U S A 1999,96(1):5–7. 10.1073/pnas.96.1.5PubMed CentralView ArticlePubMedGoogle Scholar
  30. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ: A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998,187(8):1349–1354. 10.1084/jem.187.8.1349PubMed CentralView ArticlePubMedGoogle Scholar
  31. Imai H, Chan EK, Kiyosawa K, Fu XD, Tan EM: Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J Clin Invest 1993,92(5):2419–2426. 10.1172/JCI116848PubMed CentralView ArticlePubMedGoogle Scholar
  32. Soo Hoo L, Zhang JY, Chan EK: Cloning and characterization of a novel 90 kDa ‘companion’ auto-antigen of p62 overexpressed in cancer. Oncogene 2002,21(32):5006–5015. 10.1038/sj.onc.1205625View ArticlePubMedGoogle Scholar
  33. Zhang JY, Tan EM: Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev Mol Diagn 2010,10(3):321–328. 10.1586/erm.10.12PubMed CentralView ArticlePubMedGoogle Scholar
  34. Zhang JY, Zhu W, Imai H, Kiyosawa K, Chan EK, Tan EM: De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin Exp Immunol 2001,125(1):3–9. 10.1046/j.1365-2249.2001.01585.xPubMed CentralView ArticlePubMedGoogle Scholar
  35. Tripathi K, Parnaik VK: Differential dynamics of splicing factor SC35 during the cell cycle. J Biosci 2008,33(3):345–354. 10.1007/s12038-008-0054-3View ArticlePubMedGoogle Scholar
  36. Wu H, Sun S, Tu K, Gao Y, Xie B, Krainer AR, Zhu J: A splicing-independent function of SF2/ASF in microRNA processing. Mol Cell 2010,38(1):67–77. 10.1016/j.molcel.2010.02.021PubMed CentralView ArticlePubMedGoogle Scholar
  37. Filippov V, Schmidt EL, Filippova M, Duerksen-Hughes PJ: Splicing and splice factor SRp55 participate in the response to DNA damage by changing isoform ratios of target genes. Gene 2008,420(1):34–41. 10.1016/j.gene.2008.05.008PubMed CentralView ArticlePubMedGoogle Scholar
  38. Jung DJ, Na SY, Na DS, Lee JW: Molecular cloning and characterization of CAPER, a novel coactivator of activating protein-1 and estrogen receptors. J Biol Chem 2002,277(2):1229–1234. 10.1074/jbc.M110417200View ArticlePubMedGoogle Scholar
  39. Dowhan DH, Hong EP, Auboeuf D, Dennis AP, Wilson MM, Berget SM, O’Malley BW: Steroid hormone receptor coactivation and alternative RNA splicing by U2AF65-related proteins CAPERalpha and CAPERbeta. Mol Cell 2005,17(3):429–439. 10.1016/j.molcel.2004.12.025View ArticlePubMedGoogle Scholar
  40. Huang G, Zhou Z, Wang H, Kleinerman ES: CAPER-alpha alternative splicing regulates the expression of vascular endothelial growth factor(1)(6)(5) in Ewing sarcoma cells. Cancer 2012,118(8):2106–2116. 10.1002/cncr.26488PubMed CentralView ArticlePubMedGoogle Scholar
  41. Dutta J, Fan G, Gelinas C: CAPERalpha is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel/NF-kappaB oncoprotein v-Rel. J Virol 2008,82(21):10792–10802. 10.1128/JVI.00903-08PubMed CentralView ArticlePubMedGoogle Scholar
  42. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC: A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999,19(2):1262–1270.PubMed CentralView ArticlePubMedGoogle Scholar
  43. Liao B, Hu Y, Herrick DJ, Brewer G: The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 2005,280(18):18517–18524.View ArticlePubMedGoogle Scholar
  44. Mueller-Pillasch F, Lacher U, Wallrapp C, Micha A, Zimmerhackl F, Hameister H, Varga G, Friess H, Buchler M, Beger HG, Vila MR, Adler G, Gress TM: Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997,14(22):2729–2733. 10.1038/sj.onc.1201110View ArticlePubMedGoogle Scholar
  45. Ross J, Lemm I, Berberet B: Overexpression of an mRNA-binding protein in human colorectal cancer. Oncogene 2001,20(45):6544–6550. 10.1038/sj.onc.1204838View ArticlePubMedGoogle Scholar
  46. Ross AF, Oleynikov Y, Kislauskis EH, Taneja KL, Singer RH: Characterization of a beta-actin mRNA zipcode-binding protein. Mol Cell Biol 1997,17(4):2158–2165.PubMed CentralView ArticlePubMedGoogle Scholar
  47. Doyle GA, Betz NA, Leeds PF, Fleisig AJ, Prokipcak RD, Ross J: The c-myc coding region determinant-binding protein: a member of a family of KH domain RNA-binding proteins. Nucleic Acids Res 1998,26(22):5036–5044. 10.1093/nar/26.22.5036PubMed CentralView ArticlePubMedGoogle Scholar
  48. Leeds P, Kren BT, Boylan JM, Betz NA, Steer CJ, Gruppuso PA, Ross J: Developmental regulation of CRD-BP, an RNA-binding protein that stabilizes c-myc mRNA in vitro. Oncogene 1997,14(11):1279–1286. 10.1038/sj.onc.1201093View ArticlePubMedGoogle Scholar
  49. Deshler JO, Highett MI, Abramson T, Schnapp BJ: A highly conserved RNA-binding protein for cytoplasmic mRNA localization in vertebrates. Curr Biol 1998,8(9):489–496. 10.1016/S0960-9822(98)70200-3View ArticlePubMedGoogle Scholar
  50. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grenman R, Kast J, Kallunki T, Sears R, Kahari VM, Westermarck J: CIP2A inhibits PP2A in human malignancies. Cell 2007,130(1):51–62. 10.1016/j.cell.2007.04.044View ArticlePubMedGoogle Scholar
  51. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thezenas S, Westermarck J: CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2009,15(16):5092–5100. 10.1158/1078-0432.CCR-08-3283View ArticlePubMedGoogle Scholar
  52. Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimaki A: MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 2009,101(11):793–805. 10.1093/jnci/djp103View ArticlePubMedGoogle Scholar
  53. Basile JR, Czerninski R: The role of CIP2A in oral squamous cell carcinoma. Cancer Biol Ther 2010,10(7):700–702. 10.4161/cbt.10.7.13151View ArticlePubMedGoogle Scholar
  54. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, Wang EH: CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 2011,18(3):857–865. 10.1245/s10434-010-1313-8View ArticlePubMedGoogle Scholar
  55. Vaarala MH, Vaisanen MR, Ristimaki A: CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 2010, 29: 136. 10.1186/1756-9966-29-136PubMed CentralView ArticlePubMedGoogle Scholar
  56. Qu W, Li W, Wei L, Xing L, Wang X, Yu J: CIP2A is overexpressed in esophageal squamous cell carcinoma. Med Oncol 2012,29(1):113–118. 10.1007/s12032-010-9768-9View ArticlePubMedGoogle Scholar
  57. Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE: Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 2011,117(24):6660–6668. 10.1182/blood-2010-08-304477View ArticlePubMedGoogle Scholar
  58. Chen YT, Gure AO, Scanlan MJ: Serological analysis of expression cDNA libraries (SEREX): an immunoscreening technique for identifying immunogenic tumor antigens. Methods Mol Med 2005, 103: 207–216.PubMedGoogle Scholar
  59. Minenkova O, Pucci A, Pavoni E, De Tomassi A, Fortugno P, Gargano N, Cianfriglia M, Barca S, De Placido S, Martignetti A, Felici F, Cortese R, Monaci P: Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients. Int J Cancer 2003,106(4):534–544. 10.1002/ijc.11269View ArticlePubMedGoogle Scholar
  60. Muro Y, Chan EK, Landberg G, Tan EM: A cell-cycle nuclear autoantigen containing WD-40 motifs expressed mainly in S and G2 phase cells. Biochem Biophys Res Commun 1995,207(3):1029–1037. 10.1006/bbrc.1995.1288View ArticlePubMedGoogle Scholar
  61. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995,92(25):11810–11813. 10.1073/pnas.92.25.11810PubMed CentralView ArticlePubMedGoogle Scholar
  62. Liggins AP, Guinn BA, Banham AH: Identification of lymphoma-associated antigens using SEREX. Methods Mol Med 2005, 115: 109–128.PubMedGoogle Scholar
  63. Chen G, Zhang W, Cao X, Li F, Liu X, Yao L: Serological identification of immunogenic antigens in acute monocytic leukemia. Leuk Res 2005,29(5):503–509. 10.1016/j.leukres.2004.09.013View ArticlePubMedGoogle Scholar
  64. Scanlan MJ: Identification of human tumor antigens by serological analysis of recombinant cDNA expression libraries (SEREX). Curr Protoc Immunol 2005,Chapter 20(Unit 20):27.Google Scholar
  65. Smith GP: Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985,228(4705):1315–1317. 10.1126/science.4001944View ArticlePubMedGoogle Scholar
  66. Ohyama K, Kuroda N: Proteomic approaches to profiling the humoral immune response and identifying disease-associated antigens. Biol Pharm Bull 2012,35(9):1409–1412.View ArticlePubMedGoogle Scholar
  67. Looi KS, Nakayasu ES, Diaz RA, Tan EM, Almeida IC, Zhang JY: Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. J Proteome Res 2008,7(9):4004–4012. 10.1021/pr800273hPubMed CentralView ArticlePubMedGoogle Scholar
  68. Zhang J, Wang K, Liu SS, Dai L, Zhang JY: Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. J Proteome Res 2011,10(6):2863–2872. 10.1021/pr200141cPubMed CentralView ArticlePubMedGoogle Scholar
  69. Zhang JY, Looi KS, Tan EM: Identification of tumor-associated antigens as diagnostic and predictive biomarkers in cancer. Methods Mol Biol 2009, 520: 1–10. 10.1007/978-1-60327-811-9_1PubMed CentralView ArticlePubMedGoogle Scholar
  70. Covini G, von Muhlen CA, Pacchetti S, Colombo M, Chan EK, Tan EM: Diversity of antinuclear antibody responses in hepatocellular carcinoma. J Hepatol 1997,26(6):1255–1265. 10.1016/S0168-8278(97)80460-6View ArticlePubMedGoogle Scholar
  71. Zhang JY, Wang X, Peng XX, Chan EK: Autoantibody responses in Chinese hepatocellular carcinoma. J Clin Immunol 2002,22(2):98–105. 10.1023/A:1014483803483View ArticlePubMedGoogle Scholar
  72. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM: Autoantibody signatures in prostate cancer. N Engl J Med 2005,353(12):1224–1235. 10.1056/NEJMoa051931View ArticlePubMedGoogle Scholar
  73. Koziol JA, Zhang JY, Casiano CA, Peng XX, Shi FD, Feng AC, Chan EK, Tan EM: Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003,9(14):5120–5126.PubMedGoogle Scholar
  74. Yamamoto A, Shimizu E, Takeuchi E, Houchi H, Doi H, Bando H, Ogura T, Sone S: Infrequent presence of anti-c-Myc antibodies and absence of c-Myc oncoprotein in sera from lung cancer patients. Oncology 1999,56(2):129–133. 10.1159/000011953View ArticlePubMedGoogle Scholar
  75. Zhang JY, Megliorino R, Peng XX, Tan EM, Chen Y, Chan EK: Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J Hepatol 2007,46(1):107–114.PubMed CentralView ArticlePubMedGoogle Scholar
  76. Yisraeli JK: VICKZ proteins: a multi-talented family of regulatory RNA-binding proteins. Biol Cell 2005,97(1):87–96. 10.1042/BC20040151View ArticlePubMedGoogle Scholar

Copyright

© Dai et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.